These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7308256)

  • 1. Chemoimmunotherapy for metastatic malignant melanoma using vincristine (NSC-67574), DTIC (NSC-45388) and Bacillus Calmette-Guerin.
    Thatcher N; Blackledge G; Palmer MK; Crowther D
    Eur J Cancer (1965); 1981 Apr; 17(4):465-9. PubMed ID: 7308256
    [No Abstract]   [Full Text] [Related]  

  • 2. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Pullmann H; Muth M
    Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
    [No Abstract]   [Full Text] [Related]  

  • 4. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T; Estapé J; Viñolas N; Mascaró JM; Castro J; Vilalta A; Gratacós R; Daniels M; Palou J; Grau JJ
    Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazole carboxamide and bacillus calmette--guérin.
    Gutterman JU; Mavligit G; Gottlieb JA; Burgess MA; McBride CE; Einhorn L; Freireich EJ; Hersh EM
    N Engl J Med; 1974 Sep; 291(12):592-7. PubMed ID: 4851001
    [No Abstract]   [Full Text] [Related]  

  • 8. DTIC (nsc-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065).
    Carter RD; Krementz ET; Hill GJ; Metter GE; Fletcher WS; Golomb FM; Grage TB; Minton JP; Sparks FC
    Cancer Treat Rep; 1976 May; 60(5):601-9. PubMed ID: 991149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of a nonrandomized trial in malignant melanoma patients (Clark's stages III--V) treated by post-surgical chemoimmunotherapy.
    Serrou B; Pujol H; Domas J; Gauci L
    Recent Results Cancer Res; 1978; 68():363-6. PubMed ID: 752871
    [No Abstract]   [Full Text] [Related]  

  • 11. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
    Knost JA; Reynolds V; Greco FA; Oldham RK
    J Surg Oncol; 1982 Mar; 19(3):165-70. PubMed ID: 7040820
    [No Abstract]   [Full Text] [Related]  

  • 13. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
    Peter HH; Deutschmann KE; Deinhardt J; Deicher H
    Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized prospective trial of DTIC (NSC-45388) alone versus BCNU (NSC-409962) plus vincristine (NSC-67574) in the treatment of metastatic malignant melanoma.
    Bellett RE; Mastrangelo MJ; Laucius JF; Bodurtha AJ
    Cancer Treat Rep; 1976 May; 60(5):595-600. PubMed ID: 791478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cyclophosphamide, vincristine and D.T.I.C. +/- B.C.G. in the treatment of malignant melanoma.
    Byrne MJ; Reynolds PM
    Aust N Z J Med; 1982 Aug; 12(4):263-6. PubMed ID: 6958237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination cytotoxic chemotherapy for metastatic cutaneous malignant melanoma with DTIC, BCNU, and vincristine.
    Carmo-Pereira J; Oliveira Costa F; Pimentel P
    Cancer Treat Rep; 1976 Sep; 60(9):1381-3. PubMed ID: 1016972
    [No Abstract]   [Full Text] [Related]  

  • 17. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monocytopoiesis in malignant melanoma: untreated, during immunotherapy and chemoimmunotherapy.
    Schmitt E; Meuret G; Waldermann F; Hagedorn M
    Arch Dermatol Res; 1979 May; 264(3):319-26. PubMed ID: 464648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
    Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM; Hutchins GM
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.